Plasma disposition of capecitabine (CCB) and its metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouracil (5'-DFUR) with two different capecitabine/oxaliplatin dosage regimens.
Farkouh
A
A
Department of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna, Austria. andre.farkouh@univie.ac.at
Schueller
J
J
Scheithauer
W
W
Czejka
M
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D005467:Floxuridine / Q000097:blood*; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D006801:Humans; D009944:Organoplatinum Compounds / Q000008:administration & dosage*; D000077150:Oxaliplatin
D009944:Organoplatinum Compounds; D005467:Floxuridine; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000069287:Capecitabine; C418208:5'-deoxy-5-fluorocytidine; D005472:Fluorouracil; C025034:doxifluridine